|
| 36223548 | IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression. | Mol Cancer Ther | 2023 |
| 37444561 | Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth. | Cancers (Basel) | 2023 |
| 35021863 | A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma. | Cancer Biother Radiopharm | 2022 |
| 35499569 | Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2022 |
| 36249692 | Improved Uveal Melanoma Copy Number Subtypes Including an Ultra-High-Risk Group. | Ophthalmol Sci | 2022 |
| 36212499 | Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases. | Front Oncol | 2022 |
| 36229663 | Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. | Nat Med | 2022 |
| 35254876 | Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. | J Clin Oncol | 2022 |
| 35236927 | Review of bi-specific therapies in uveal melanoma. | Cancer Gene Ther | 2022 |
| 33208912 | BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors. | Oncogene | 2021 |
| 36276251 | Conditional survival of uveal melanoma using The Cancer Genome Atlas (TCGA) classification (Simplified Version) in 1001 cases. | Saudi J Ophthalmol | 2021 |
| 33882197 | Orthotopic Human Metastatic Uveal Melanoma Xenograft Mouse Models: Applications for Understanding the Pathophysiology and Therapeutic Management of Metastatic Uveal Melanoma. | Curr Protoc | 2021 |
| 33763694 | A case of meningitis due to extensively drug-resistant Pseudomonas aeruginosa imported through medical evacuation: genomic and environmental investigation. | J Travel Med | 2021 |
| 33568347 | Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <i>GNAQ</i>-Driven Uveal Melanoma. | Clin Cancer Res | 2021 |
| 33510355 | Correction to: BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors. | Oncogene | 2021 |
| 33806615 | Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma. | Cancers (Basel) | 2021 |
| 34389658 | Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <i>GNAQ</i>-Driven Uveal Melanoma. | Clin Cancer Res | 2021 |
| 34771666 | Genetic Landscape and Emerging Therapies in Uveal Melanoma. | Cancers (Basel) | 2021 |
| 34771620 | The Role of HGF/MET Signaling in Metastatic Uveal Melanoma. | Cancers (Basel) | 2021 |
| 34371020 | Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs. | J Biol Chem | 2021 |
| 31283110 | IsomiRs and tRNA-derived fragments are associated with metastasis and patient survival in uveal melanoma. | Pigment Cell Melanoma Res | 2020 |
| 31906411 | An Outcome Assessment of a Single Institution's Longitudinal Experience with Uveal Melanoma Patients with Liver Metastasis. | Cancers (Basel) | 2020 |
| 32050636 | Expression of Tryptophan 2,3-Dioxygenase in Metastatic Uveal Melanoma. | Cancers (Basel) | 2020 |
| 32976223 | A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma. | Melanoma Res | 2020 |
| 32997782 | Rapid, Fatal Acute Right Ventricular Failure After Locoregional Cytokine Therapy for Uveal Melanoma Liver Metastases. | Tex Heart Inst J | 2020 |
| 32681908 | Unique Geospatial Accumulations of Uveal Melanoma. | Am J Ophthalmol | 2020 |
| 32434572 | Development and optimization of orthotopic liver metastasis xenograft mouse models in uveal melanoma. | J Transl Med | 2020 |
| 32430489 | Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma. | Mol Cancer Ther | 2020 |
| 30610113 | Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma. | EMBO Mol Med | 2019 |
| 31762467 | Generation of a Liver Orthotopic Human Uveal Melanoma Xenograft Platform in Immunodeficient Mice. | J Vis Exp | 2019 |
| 31453767 | A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis. | Radiology | 2019 |
| 30833489 | First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. | Oncologist | 2019 |
| 31010434 | Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. | J Immunother Cancer | 2019 |
| 30567972 | Effects of Oncogenic Gα<sub>q</sub> and Gα<sub>11</sub> Inhibition by FR900359 in Uveal Melanoma. | Mol Cancer Res | 2019 |
| 28935400 | Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma: Comparison with Institutional Controls. | Ophthalmology | 2018 |
| 29689030 | CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. | Retina | 2018 |
| 27921276 | Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. | J Cancer Res Clin Oncol | 2017 |
| 28138035 | Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. | Mol Cancer Ther | 2017 |
| 28162021 | Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. | Expert Rev Clin Pharmacol | 2017 |
| 28129639 | Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment. | Oncotarget | 2017 |
| 29185395 | PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. | Immunotherapy | 2017 |
| 29141225 | A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. | Cell Rep | 2017 |
| 28754534 | Health-related quality of life during trans-arterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for unresectable hepatic metastases from ocular melanoma. | Am J Surg | 2017 |
| 28508253 | Image-Guided Transarterial Chemoembolization With Drug-Eluting Beads Loaded with Doxorubicin (DEBDOX) for Unresectable Hepatic Metastases from Melanoma: Technique and Outcomes. | Cardiovasc Intervent Radiol | 2017 |
| 28645290 | Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis. | J Transl Med | 2017 |
| 28816150 | Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases. | Int J Radiat Oncol Biol Phys | 2017 |
| 24441583 | Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography. | Am J Clin Oncol | 2016 |
| 26613897 | Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization. | Am J Pathol | 2016 |
| 27028970 | Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity? | Rev Recent Clin Trials | 2016 |
| 26837440 | Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T). | Future Oncol | 2016 |